Shares of Intra-Cellular Therapies (NASDAQ: ITCI) increased by nearly 15% last week after the company reached a significant settlement with Sandoz in the ongoing Caplyta (lumateperone) patent litigation. The announcement, which coincides with major industry developments, underscores ITCI's market position and strategic foresight. Settlement Details The litigation arose from Sandoz’s... Read More

Moderna recently registered a significant triumph in its ongoing patent dispute concerning its Covid-19 vaccine against Pfizer and BioNTech. The European Patent Office (EPO) upheld the legitimacy of a key Moderna patent in an oral verdict, boosting the company's stance in its legal battle. The validated patent, known as the... Read More

As the relentless march of time continues, pharmaceutical executives find themselves facing the inevitability of patent expirations and the subsequent entry of generic or biosimilar competition. This reality underscores the imperative for continual innovation and new product launches to offset revenue losses from drugs facing the patent cliff. In a... Read More

BeiGene, a biotechnology company, has taken legal action by filing patent infringement lawsuits against pharmaceutical companies Sandoz and MSN Pharmaceuticals, along with MSN Laboratories Private Ltd. This move targets the defendants' attempts to market a generic version of the cancer drug BRUKINSA® (zanubrutinib). The lawsuits, filed in the United States... Read More

Shares of UroGen Pharma (NASDAQ: URGN) took a minor premarket hit following news that Teva Pharmaceutical (NYSE: TEVA) has submitted an application seeking FDA approval for a generic version of UroGen's bladder cancer therapy, Jelmyto. The move by Teva comes as they aim to enter the market with their own... Read More